Clinical trial KEYNOTE-355
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355)
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | MSD (Merck Sharp & Dohme) |
EudraCT Identifier | 2016-001432-35 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02819518 |
Inclusion criteria | Triple negative. Metastatic. 1s Line |
Last update |